A Global View: NanoLogix Creates Science Advisory Board
May 11 2009 - 8:45AM
PR Newswire (US)
HUBBARD, Ohio, May 11 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(Pink Sheets: NNLX) is pleased to announce the creation of its
Science Advisory Board to help evaluate and target research and
development efforts for products. The new advisory board provides
the company with a vastly expanded scope of expertise in both
medicine and biomedical research. Dr. Robert Ollar, NanoLogix
cofounder and author of numerous NanoLogix patents, has resigned
from the NanoLogix Board of Directors to assume the position of
Chairman of the Science Advisory Board. NanoLogix Science Advisory
Board Members Dr. Robert A. Ollar, M. Sc., Ph.D. Chairman of the
Science Advisory Board. Dr. Ollar is the director of the Core
Molecular Biology Program of the Department of Surgery at St.
Vincent's Hospital in Manhattan. He is also an Assistant Professor
at New York Medical College. His background includes work in
scientific research, medical education, and biotechnology. He
brings to the Board decades of experience in the fields of medical
microbiology, mycobacteriology, medical mycology, and molecular
biology. He serves as advisor to the WHO Global Stop TB
Partnership, CDC TB Training and Educational Network, and the
Mahatma Gandhi Institute for Medical Sciences in India in the
fields of TB and AIDS-related mycobacterial Diseases. Dr. Ollar's
current focus is on the development of molecular technologies for
rapid detection of pancreatic and colorectal cancers. Sergey V.
Gazenko, Ph.D., NanoLogix Vice-President of Research and
Development. Dr. Gazenko holds his doctoral degree from The
Institute of Applied Biochemistry in Moscow. Dr. Gazenko has worked
for more than 28 years in the area of microbiological diagnostics
and is the author of numerous scientific publications and patents.
He is the author of both granted and patents pending for BNP(TM)
and BNC(TM) rapid test kits. His current focus is on enhancements
to both BNP and BNC technologies. Dr. Brian Caplin, Ph.D. Dr.
Caplin holds a doctorate in the fields of biochemistry and
molecular biology. He is an internationally respected expert in the
new field of Real Time Polymerase Chain Reaction and is president
of his own firm, Fluoresentric, Inc. He brings to the advisory
board an extensive insight into the links of traditional
growth-based technologies to the expanding world of real time
diagnostics and microarray-based systems for the identification of
large panels of microbial pathogens, important in areas such as
medical veterinary microbiology and biodefense. Dr. T. Dorai,
M.Sc., Ph.D. Associate Professor and Director of Research,
Department of Urology, Saint Vincent's Hospital and New York
Medical College, Manhattan. Dr. Dorai has broad based skills in the
fields of microbiology, immunology, biochemistry and molecular
biology. As a professor and researcher at numerous institutes in
India, Los Angeles and New York City, and with 47 publications to
his name, Dr. Dorai reflects a global perspective shared by other
board members. Dr. Sushil Duddempudi, MD Assistant Professor of
Medicine, Texas A&M Health Science Center, Temple, Texas. Dr.
Duddempudi is a physician and gastroenterologist with unique
insights into medical needs for specific types of diagnostic
technology and methodologies. His knowledge of gastrointestinal
disease provides NanoLogix with a specialized understanding of the
unique problems associated with gastrointestinal infections, such
as salmonella, cholera, and campylobacteria. Dr. Deepak Kumar
Mendiratta, MD, Ph.D. Dr. Mendiratta is chairman of the Department
of Microbiology at the Mahatma Gandhi Institute of Medical
Sciences. He holds both scientific and medical graduate and
post-graduate credentials. Dr. Mrs. P. Narang, MD Dr. Narang is an
internationally respected physician in the fields of microbiology,
medical education, and public health. Formerly dean of the Mahatma
Gandhi Institute of Medical Science, and chairman of its Department
of Microbiology, she has lectured worldwide on Public Health topics
related to infections disease pathogens, especially in the realm of
Global TB. Dr. Narang pioneered the field of AIDS-related
non-tuberculous mycobacterial research in India, increasing
awareness throughout India of the importance of prompt
identification and treatment of these pathogens in the Indian AIDS
patient population. Dr. Ravinder Narang, MD An internationally
respected surgeon and educator, Dr. Narang has written extensively
on infectious disease and oncology and participated in numerous
programs involving both national and international (WHO) public
health agencies. He brings to the Science Advisory Board a
surgeon's unique perspective on operative and post-operative
complications related to infectious agents. Cliff Watts, MD Dr.
Watts has been an Emergency Room physician for almost thirty-five
years. During his tenure at Boulder Community Hospital, Dr. Watts
has often been on the front line of treating patients with life
threatening diseases, and has a practical understanding of the
needs in rapid response medicine. His contribution to the board is
based upon extensive practical experience in urgent care, public
health, and time-sensitive response to treatment. Chris Novak,
NanoLogix Director of Intellectual Property. Mr. Novak is a
registered patent attorney and is licensed to practice law in
several states. Mr. Novak earned a Juris Doctor (J.D.) degree from
Marquette University where he also earned a BSME. He also holds a
MSEE degree from California Polytechnic State University, and is
currently working towards a degree in biotechnical science. About
NanoLogix, Inc. NanoLogix is a biotechnology company focused
primarily on medical diagnostics. Its products offer accelerated
detection and identification of microorganisms present in
infectious and non-infectious human diseases, such as tuberculosis,
NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and
plague. In addition to medical, Defense, and homeland security
applications, NanoLogix technology is applicable in pharmaceutical,
industrial, veterinary and environmental testing. Patents granted
to NanoLogix can be used in the areas of applied microbiology, soil
microbiology and bioremediation, microbial physiology, molecular
biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity,
stem-cell research, and bioreactor-based hydrogen generation. More
information on NanoLogix is available at: http://www.nanologix.com/
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results. Contact: NanoLogix, Inc. Investor Relations
Carol Surrena Telephone: 330-534-0800 E-mail: DATASOURCE:
NanoLogix, Inc. CONTACT: Carol Surrena, Investor Relations of
NanoLogix, Inc., +1-330-534-0800, Web Site:
http://www.nanologix.com/
Copyright